Helping Ensure Safer Immunotherapies: From Gene Editing To Next-Generation Sequencing (NGS)-Based T Cell Characterization

Immune checkpoint inhibitors have reshaped cancer care, yet many patients see limited benefit and face immune-related toxicities. Advances in gene editing are opening new possibilities to refine T cell therapies, enabling precise control over checkpoint pathways such as PD-1 and TIGIT. By engineering tumor-infiltrating lymphocytes (TILs) derived from melanoma metastases, researchers are uncovering ways to enhance anti-tumor activity while improving safety profiles. Equally important is the role of integrated genomic workflows in translating these innovations into actionable insight. From high-quality nucleic acid extraction to NGS-based transcriptomic analysis, streamlined and automated processes are revealing the gene expression changes that drive T cell function.

Discover how combining cell engineering with robust genomic analysis can accelerate therapeutic development and inform smarter lead selection decisions.